Harvoni Treatment Porphyria Cutanea Tarda

Status Completed

Clinical Trial Summary

In the medical literature there case reports that Harvoni improves symptoms in patients with PCT. However, this has never been systematically tested. Therefore, the purpose of this study is to assess whether Harvoni alone is an effective therapy of active PCT in patients with Chronic Hepatitis C.

Clinical Trial Description

This is a clinical trial, which means its purpose is to study an intervention or treatment. In this study all patients with PCT will be given a standard dose of Harvoni and monitored for two years. Currently there are two standard therapies for PCT, phlebotomies (removing certain amounts of blood at specific intervals), or low dose hydroxychloroquine (an oral pill). These treatments are used for patients with PCT whether or not they also have HCV. For patients with HCV however, we do not know whether treating the HCV first will also resolve the PCT symptoms. There will be an initial visit to determine whether participants are eligible to be in the study. If a participant is found to be eligible, he/she will be asked come to the study site once every month over the course of one year, and then once every 3 months for an additional year. There will be approximately 17 visits over the course of the whole study. At these visits the study doctors will check in with the participant and some blood and urine samples will be taken. Participants will not be charged for any of the lab tests that are being done as a part of this study alone. All participants in this study will receive the Harvoni pills at no cost to them. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03118674
Study type	Interventional
Source	Wake Forest University Health Sciences
Contact
Status	Completed
Phase	Phase 2
Start date	September 6, 2017
Completion date	March 4, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03686722` - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin	Phase 1
Recruiting	`NCT04510246` - Link Hepatitis C Notifications to Treatment in Tasmania	N/A
Completed	`NCT03413696` - Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
Completed	`NCT03109457` - Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
Completed	`NCT01458054` - Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults	Phase 1
Completed	`NCT03740230` - An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
Completed	`NCT03426787` - Helping Empower Liver and Kidney Patients	N/A
Completed	`NCT03627299` - Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors	Phase 4
Completed	`NCT00006301` - Immune Response to Hepatitis C Virus
Active, not recruiting	`NCT03949764` - The Kentucky Viral Hepatitis Treatment Study	Phase 4
Completed	`NCT03365635` - Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C	Phase 4
Recruiting	`NCT04405024` - Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients	N/A
Completed	`NCT04525690` - Improving Inpatient Screening for Hepatitis C	N/A
Completed	`NCT04033887` - Evaluation Study of RDTs Detecting Antibodies Against HCV
Withdrawn	`NCT04546802` - HepATocellular Cancer Hcv Therapy Study	Phase 3
Active, not recruiting	`NCT02961426` - Strategic Transformation of the Market of HCV Treatments	Phase 2/Phase 3
Completed	`NCT02992184` - PoC-HCV Genedrive Viral Detection Assay Validation Study	N/A
Completed	`NCT03186313` - A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection	Phase 3
Completed	`NCT02869776` - Integrating HCV and HIV Screening During the Era of HIV Antigen Testing	N/A
Completed	`NCT02705534` - Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1	Phase 3